Alpha Tau Medical Ltd. (DRTS) is a Biotechnology company in the Healthcare sector, currently trading at $7.83. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is DRTS = $12 (+53.3% upside).
Valuation: DRTS trades at a trailing Price-to-Earnings (P/E) of -14.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.88.
Net income is $43M (loss), growing at -9.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $14M against $77M equity (Debt-to-Equity (D/E) ratio 0.18, conservative). Current ratio is 7.45 (strong liquidity). Debt-to-assets is 12.9%. Total assets: $107M.
Analyst outlook: 3 / 4 analysts rate DRTS as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 94/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 34/100 (Fail), Future 85/100 (Pass), Income ?/100 (Fail).
